Cargando…

MRI predictors of pharmacotherapy response in major depressive disorder

Major depressive disorder is among the most prevalent psychiatric disorders, exacting a substantial personal, social, and economic toll. Antidepressant treatment typically involves an individualized trial and error approach with an inconsistent success rate. Despite a pressing need, no reliable biom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerlach, Andrew R., Karim, Helmet T., Peciña, Marta, Ajilore, Olusola, Taylor, Warren D., Butters, Meryl A., Andreescu, Carmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420953/ https://www.ncbi.nlm.nih.gov/pubmed/36027717 http://dx.doi.org/10.1016/j.nicl.2022.103157

Ejemplares similares

Acute trajectories of neural activation predict remission to pharmacotherapy in late-life depression
por: Karim, Helmet T., et al.
Publicado: (2018)

Intrinsic functional connectivity in late-life depression: trajectories over the course of pharmacotherapy in remitters and non-remitters
por: Karim, H T, et al.
Publicado: (2017)

Networks of worry—towards a connectivity-based signature of late-life worry using higher criticism
por: Gerlach, Andrew R., et al.
Publicado: (2021)

Understanding the Neurocomputational Mechanisms of Antidepressant Placebo Effects
por: Peciña, Marta, et al.
Publicado: (2021)

Neural Implications of Psychotherapy, Pharmacotherapy, and Combined Treatment in Major Depressive Disorder
por: Schwartz, Thomas L., et al.
Publicado: (2016)

The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder
por: Arnaud, Alix, et al.
Publicado: (2021)

Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?
por: Cosci, Fiammetta, et al.
Publicado: (2021)

Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine
por: Stein, Dan J.
Publicado: (2023)

Multimodal Brain Connectivity Analysis in Unmedicated Late-Life Depression
por: Tadayonnejad, Reza, et al.
Publicado: (2014)

Predictors of recurrence of major depressive disorder
por: Lye, Munn-Sann, et al.
Publicado: (2020)

In the grip of worry: cerebral blood flow changes during worry induction and reappraisal in late-life generalized anxiety disorder
por: Karim, H T, et al.
Publicado: (2017)

In the grip of worry: cerebral blood flow changes during worry induction and reappraisal in late-life generalized anxiety disorder
por: Karim, H T, et al.
Publicado: (2017)

Impact of symptomatic menopausal transition on the occurrence of depression, anxiety, and sleep disorders: A real-world multi-site study
por: Lee, Dong Yun, et al.
Publicado: (2023)

Reliability, Convergent Validity and Time Invariance of Default Mode Network Deviations in Early Adult Major Depressive Disorder
por: Bessette, Katie L., et al.
Publicado: (2018)

The pharmacotherapy of depression with EPA
por: Puri, Basant K
Publicado: (2010)

Predictors of Major Depressive Disorder in Older People
por: Sousa, Susana, et al.
Publicado: (2021)

Mild cognitive impairment and major depressive disorder are associated with molecular senescence abnormalities in older adults
por: Diniz, Breno S., et al.
Publicado: (2021)

Catatonia in a case of major depression resistant to pharmacotherapy. A case report
por: Gil Sánchez, C. M., et al.
Publicado: (2023)

Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
por: Lin, Chemin, et al.
Publicado: (2019)

The rise and fall of MRI studies in major depressive disorder
por: Zhuo, Chuanjun, et al.
Publicado: (2019)

The Influence of Alcohol on Rumination and Metacognitions in Major Depressive Disorder
por: Gawron, Lana, et al.
Publicado: (2022)

Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report
por: Husain, M. I., et al.
Publicado: (2023)

Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study
por: Del Casale, Antonio, et al.
Publicado: (2022)

Evaluation of Endocrine Parameters as Predictor of Major Depressive Disorder
por: Gupta, Soma, et al.
Publicado: (2017)

Predictors of Electroconvulsive Therapy Outcome in Major Depressive Disorder
por: Su, Liang, et al.
Publicado: (2022)

Pharmacotherapy of panic disorder
por: Pull, Charles B, et al.
Publicado: (2008)

PS232. Influence of alexithymia on the prognosis of patients with major depression treated using pharmacotherapy.
por: Mantani, Tomoyuki, et al.
Publicado: (2016)

Prediction of remission in pharmacotherapy of untreated major depression: development and validation of multivariable prediction models
por: Furukawa, Toshi A., et al.
Publicado: (2019)

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders
por: Wolff, Jan, et al.
Publicado: (2021)

Aberrant pulvinar effective connectivity in generalized social anxiety disorder
por: Tadayonnejad, Reza, et al.
Publicado: (2016)

Cognitive Considerations in Major Depression: Evaluating the Effects of Pharmacotherapy and ECT on Mood and Executive Control Deficits
por: Spagna, Alfredo, et al.
Publicado: (2022)

The fire this time: The stress of racism, inflammation and COVID-19
por: Ajilore, Olusola, et al.
Publicado: (2020)

Pharmacotherapy of Insomnia
por: Neubauer, David N, et al.
Publicado: (2018)

Can the Addition of Maintenance Electroconvulsive Therapy to Pharmacotherapy Improve Relapse Prevention in Severe Major Depressive Disorder? A Randomized Controlled Trial
por: Martínez-Amorós, Erika, et al.
Publicado: (2021)

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
por: Rong, Carola, et al.
Publicado: (2018)

Pharmacotherapy for acid/peptic disorders.
por: Schubert, M. L.
Publicado: (1996)

Challenges in the Pharmacotherapy of Urogenital Disorders
por: Michel, Martin C.
Publicado: (2010)

Maintenance Pharmacotherapies for Neuropsychiatric Disorders
por: Richards, Stephanie
Publicado: (2013)

Update on Pharmacotherapy in Psychodermatological Disorders
por: Shenoi, Shrutakirthi D., et al.
Publicado: (2020)

Pharmacotherapy in patients with vasomotor disorders
por: Boerhout, C.K.M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jn9n3n14ucm5040cno1td001es